🔄

Vitelliform Macular Dystrophy Treatment

Best disease, also known as Best vitelliform macular dystrophy, is an inherited condition that affects the central part of the retina. This area, called the macula, is responsible for sharp, detailed vision. In patients with this condition, a fatty yellow substance builds up under the macula. This buildup often looks like a bright egg yolk during a clinical exam. While it often begins in childhood, many people do not notice vision changes until later in life.

When the egg yolk stage progresses, the yellow material can break down, leading to blurred or distorted central vision. Straight lines may look wavy, and fine details become hard to see. Because this is a genetic issue, finding a specialized Vitelliform Macular Dystrophy Treatment is essential to manage the health of your retinal cells. Early detection helps you take steps to protect your sight before significant damage occurs.

Netra Eye Institute offers a natural path for those diagnosed with Best disease. As a specialized eye care institute, we do not perform surgeries. Instead, we focus on holistic eye care to support the delicate structures of your eyes. Our goal is to stabilize the macula and improve cellular health without invasive procedures. We believe that internal balance is the key to managing degenerative eye conditions.

We provide vitelliform macular dystrophy treatment by using the principles of Traditional Chinese Medicine and Acupuncture. Our team also incorporate ayurveda eye treatment to nourish the ocular tissues and clear metabolic waste. By focusing on herbal medicines and natural therapies, we help you maintain your vision and overall wellness. Choosing our vitelliform macular dystrophy treatment ensures your eyes receive the care they need in a calm, professional environment.

In Best Disease, NRT focuses on supporting retinal function, reducing secondary stressors, and improving and preserving vision.

Neuroprotection, neurotrophins, ocular blood flow, ocular inflammation and oxidative stress can all contribute to your Glaucoma progression.

glaucoma treatment options, glaucoma neuroprotection therapy, glaucoma risks beyond pressure, glaucoma care Edison NJ / South Plainfield NJ

Why lowering IOP may not be enough to stop glaucoma vision loss?

Glaucoma is a neurodegenerative disease, not just a pressure disease

Glaucoma is increasingly understood as a neurodegenerative disease, not merely a condition caused by elevated eye pressure.  Mechanisms such as impaired ocular blood flow, mitochondrial dysfunction, oxidative stress, chronic inflammation, and reduced neurotrophic support, all of which contribute to neuronal injury.

Optic nerve damage isn't always caused by high eye pressure

While elevated intraocular pressure (IOP) is a major risk factor, many people develop glaucoma even with normal or low eye pressure—a condition known as normal-tension glaucoma (NTG). Recognizing glaucoma as a neurodegenerative condition underscores the need for treatment strategies that go beyond pressure control and actively support optic nerve health and neuroprotection.

Lowering IOP is important, but not always enough

Studies show that 30–40% of glaucoma patients continue to lose vision despite maintaining normal eye pressure. This highlights the need for a more comprehensive glaucoma treatment approach that goes beyond just IOP management.

Individualized care is essential

These patients may require more than just IOP-lowering treatments. For instance, neuroprotective strategies targeting the optic nerve or treatments to improve ocular blood flow to the retina and optic nerve may be considered to reduce progression.

What causes continued vision loss in glaucoma?

Multiple research studies have shown factors such as lack of neuroprotection, reduced ocular blood flow, neurotrophin deprivation, increased oxidative stress, ocular inflammation and excitotoxicity can all  contribute to vision loss progression in Glaucoma.

Increased Intraocular Pressure (IOP) Is Not The Only Risk Factor For Glaucoma. ​

Lowering intraocular pressure (IOP) with eye drops has long been the standard approach in glaucoma care. However, IOP control alone does not fully address the disease process. Many patients continue to experience optic nerve damage and vision loss despite well-controlled eye pressure, highlighting the need for a more comprehensive treatment strategy that supports optic nerve health and addresses underlying factors beyond pressure alone.

Although reducing eye pressure (IOP) remains the standard of care for glaucoma, increased eye pressure alone does not fully explain the disease, and some individuals may continue to lose vision despite achieving target IOP levels.

What is Normal Tension Glaucoma?

Normal Tension Glaucoma (NTG) is a type of glaucoma in which optic nerve damage and vision loss occur despite eye pressure remaining within the normal range. In NTG, pressure alone does not explain the disease; instead, the optic nerve is thought to be more vulnerable due to factors such as reduced blood flow, impaired circulation regulation, increased nerve sensitivity, oxidative stress, and reduced neuroprotection. Because of this heightened susceptibility, even normal eye pressure can contribute to progressive damage over time.
The mean percentage of NTG in all patients diagnosed with a glaucomatous visual field defect is between 30% and 40%.

Asians and NTG

NTG is especially common in Asian populations, where it can account for a majority of primary open-angle glaucoma (POAG) cases—often exceeding 70–90%. This highlights that glaucoma is not solely a pressure-related condition, but a complex disease influenced by overall optic nerve health and systemic factors.
The prevalence of NTG has been reported to be 92.3% in Japan, 84.6% in Singapore, 83.58% in Northern China, 82% in South India, 79.3% in Southern China, 77% in South Korea, 57.1% in South Africa, 46.9% in Iran, 38.9% in Netherlands, 31.7% in the United States, 31.0% in Iceland, and 30.0% in Italy.

Source: Normal-Tension Glaucoma: Pathogenesis, Glaucoma Today, November/December 2022

Why NTG patients needs more than eye drops?

Normal Tension Glaucoma (NTG) patients often requires more than just eye-pressure–lowering drops because eye pressure is not their main cause of glaucomatous vision loss. In NTG, vision loss can occur even when eye pressure is normal, due to reduced blood flow to the optic nerve, poor regulation of blood vessels, increased inflammation, oxidative stress, and reduced support for the nerve cells that carry visual signals to the brain. While eye drops may help lower pressure slightly and remain part of treatment, they do not improve optic nerve blood flow or protect nerve cells from ongoing injury. For this reason, NTG care often needs a broader approach that supports optic nerve health, stabilizes blood flow, and addresses the underlying factors contributing to nerve damage—beyond eye pressure alone.

Netra Restoration Therapy (NRT)

Our signature Netra Restoration Therapy is a unique treatment method available exclusively at Netra Eye Institute, which has shown to halt AMD progression, improve visual acuity, reduce foggy/hazy vision, improve contrast sensitivity and  reduce glare.
The Mechanism of Action (MOA) of Netra Restoration Therapy works by enhancing ocular blood flow through the regulation of vascular function, reducing oxidative stress and ocular inflammation, increasing neurotrophin levels and neuroprotection, and reducing ferroptosis.

Our breakthrough and revolutionized Netra Restoration Therapy (NRT) will help restore your vision. This Eye Care Therapy reduces ocular inflammation and oxidative stress, restoring normal ocular blood flow and supplying antioxidants and neuro-protection to your eyes to protect and restore your vision.

Treatment Benefits

The potential for visual improvement depends on the severity of retinal damage present at the time of treatment for Wet AMD. Taking these factors into account, our therapeutic approach has been shown to result in:

Stop Vision Loss Progression

Stops vision loss progression by reducing the ocular inflammation, regulating ocular blood flow and nourshing the retinal cells.

Improved Visual Field

Improvement in visual field by restoring
dormant and unhealthy retinal cells.

Improved Visual Acuity

An improvement of at least one line on the distance and near vision eye chart.

Improved Contrast Sensitivity

Improved contrast vision, making it easier to distinguish shapes, edges, and details.

Increased Visual Brightness

Improvement in color, brightness perception and clarity making it easier to see in low-light or nighttime conditions, thereby supporting safer mobility and daily activities.

Reduced Glare and Light Sensitivity

Reduced glare, less light sensitivity, and improved comfort in bright environments, such as sunlight, headlights, or digital screens.

Reduced Eye Strain/Pain

Patients experience considerable reduction
in eye pain and eye strains.

Improved Quality of Life

Patients often report feeling “healthier overall,” not just in their eyes.

I recently completed my three weeks of Netra Restoration Therapy  and I am already seeing major improvements with the reduction in my eye prescription correction numbers. Netra Eye Institute is not just a well equipped clinic with modern ophthalmic instruments but is also backed up by professional and patient-caring staff. Thank you Dr. Gandapodi for your services and care.

– Sarang - Grateful Netra Patient

NRT backed by scientific  research studies

Netra Restoration Therapy is grounded in contemporary biomedical research demonstrating that many eye diseases are driven by reduced ocular blood flow, ongoing neurodegeneration, and cellular stress. Scientific studies show that improving vascular regulation enhances oxygen and nutrient delivery to the retina and optic nerve, while supporting neurotrophin activity and neuroprotection helps preserve vulnerable nerve cells. At the same time, controlling oxidative stress, ferroptosis, and chronic inflammation is critical to slowing tissue damage and disease progression. Netra Restoration integrates these evidence-based principles into a comprehensive approach designed to support long-term eye health and visual function.

RESEARCH PAPERS